Citations

Clear

912 citation(s) found for "Yu, Caroline".

Abstract 182: Increased Adipose-Derived Mesenchymal Stem Cells Counts and Pro-B-Type Natriuretic Peptide in Patients With Critical Limb Ischemia
Farres, Houssam , Sutton, Caroline, Dortch, John D. , Hakaim, Albert G., Zubair, Abba C.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | July 3, 2021 | Volume: 34 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.34.suppl_1.182 Get It

Mesenchymal stem cells (MSCs) have been shown to improve regeneration of injured tissues in vivo. Several in vitro studies and animal models have demonstrated improvement in MSCs paracrine effects under hypoxic conditions. Moreover, several studies suggested that the pro B-type natriuretic peptide (pro-BNP) could be involved in the stimulation of postischemic vascular regeneration. The purpose of this study was to investigate the effect of critical limb ischemia, in a human model, on in-situ adipose derived mesenchymal stem cells (ADMSCs) and to determine whether serum levels of N-terminal pro-BNP correlate with ADMSCs counts and associated paracrine effects. Lipoaspirate samples of ≥ 10mL were collected from ischemic limbs (ischemic group) and compared to control (without ischemia). MSCs were characterized by frequency, viability, differentiation potential, cytokines expression, and cell surface markers. Serum NT pro-BNP was measured as well. MSCs counts were 9-to-10-fold higher in patients with ischemic limbs (mean 7952 MSC/mL ± 542) than controls (mean 790 MSC/mL ± 65). Pro-BNP levels (1878-4757 pg/mL) were approximately 8-to-26-fold higher than in age- and sex-matched controls. Furthermore, there were positive correlations between pro-BNP levels and MSCs counts in the ischemic group. In conclusion, patients with critical limb ischemia (CLI) have higher levels of pro-BNP and MSCs counts than controls. Increased levels of pro-BNP and MSCs counts can be considered humoral and cellular surrogates of ischemia and hypoxia in patients with CLI. This supports recent studies that suggest that the increase production of peripheral BNP may be a stem cells-mediated response to stimulate angiogenesis in the ischemic skeletal muscles.
Post‐discharge arrhythmic risk stratification of patients with acute myocarditis and life‐threatening ventricular tachyarrhythmias
Gentile, Piero , Merlo, Marco , Peretto, Giovanni , Bella, Paolo Della , Aquaro, Giovanni Donato , Potena, Luciano , Campodonico, Jeness , Foà, Alberto , Hazebroek, Mark R. , Čerček, Andreja Černe , Shrivastava, Sanskriti , Heyning, Caroline M. Van De , Craenenbroeck, Emeline M. Van , Sugimura, Koichiro , Cannatà, Antonio , Porcari, Aldostefano , Colopi, Marzia , Perkan, Andrea, Garascia, Andrea , Pereira, Naveen L. , Heymans, Stéphane , Camici, Paolo G. , Frigerio, Maria , Potena, Luciano , Van De Heyning, Caroline M , Heymans, Stephane , Porcari, Aldostefano , Foà, Alberto , Gentile, Piero , Cannatà, Antonio , Ammirati, Enrico , Sala, Simone , Imazio, Massimo , Raafs, Anne G. , Brambatti, Michela , Nucifora, Gaetano , Huang, Florent , Schmidt, Matthieu , Muser, Daniele , Aoki, Tatsuo , Shimokawa, Hiroaki , Artico, Jessica , Bussani, Rossana , Barbati, Giulia , Cipriani, Manlio , Agostoni, Piergiuseppe , Adler, Eric D , Sinagra, Gianfranco

Mayo Clinic

European Journal of Heart Failure | July 1, 2021 | Volume: 23 | Issue: 12 | Pages: 2045-2054

10.1002/ejhf.2288 | PMID 34196079 Get It

Aims The outcomes of patients presenting with acute myocarditis and life‐threatening ventricular arrhythmias (LT‐VA) are unclear. The aim of this study was to assess the incidence and predictors of recurrent major arrhythmic events (MAEs) after hospital discharge in this patient population. Methods and results We retrospectively analysed 156 patients (median age 44 years; 77% male) discharged with a diagnosis of acute myocarditis and LT‐VA from 16 hospitals worldwide. Diagnosis of myocarditis was based on histology or the combination of increased markers of cardiac injury and cardiac magnetic resonance (CMR) Lake Louise criteria. MAEs were defined as the relapse, after discharge, of sudden cardiac death or successfully defibrillated ventricular fibrillation, or sustained ventricular tachycardia (sVT) requiring implantable cardioverter‐defibrillator therapy or synchronized external cardioversion. Median follow‐up was 23 months [first to third quartile (Q1–Q3) 7–60]. Fifty‐eight (37.2%) patients experienced MAEs after discharge, at a median of 8 months (Q1–Q3 2.5–24.0 months; 60.3% of MAEs within the first year). At multivariable Cox analysis, variables independently associated with MAEs were presentation with sVT [hazard ratio (HR) 2.90, 95% confidence interval (CI) 1.38–6.11]; late gadolinium enhancement involving ≥2 myocardial segments (HR 4.51, 95% CI 2.39–8.53), and absence of positive short‐tau inversion recovery (STIR) (HR 2.59, 95% CI 1.40–4.79) at first CMR. Conclusions Among patients discharged with a diagnosis of myocarditis and LT‐VA, 37.2% had recurrences of MAEs during follow‐up. Initial CMR pattern and sVT at presentation stratify the risk of arrhythmia recurrence.
Multiple roles of ErbB4, an epidermal growth factor receptor, in zebrafish embryonic development.
Babcock, Ǵerald, Sussman, Caroline R. , Plata, Consuelo , Liang, Jennifer O.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 21 | Issue: 6 | Pages: No page available

10.1096/fasebj.21.6.a1426-c Get It

Members of the epidermal growth factor family and its receptors (EGFR/ErbBs 1–4) critically regulate the development and maintenance of numerous tissues including CNS, heart, kidney, GI tract, and muscle, accounting for a variety of congenital malformations, tumor growth, renal cyst formation, and heart failure. We cloned erbB4 from zebrafish (Danio rerio) and examined its effects on embryonic development by reducing its expression through injection of antisense morpholinos (MO) into zebrafish embryos at the 1–2 cell‐stage. Zebrafish ErbB4 was 73% identical to rat and human ErbB4. In situ hybridization using two non‐overlapping probes both showed expression 10 hours post‐fertilization throughout the embryo with expression resolving to the brain, eye, heart, kidney, and GI tract (intestine, liver, pancreas) over the next 5 days. Injection of two 5′ non‐overlapping MO both demonstrated altered development of multiple organs including brain, eyes, heart, and tail. Effects ranged in severity from complete lack of head, heart, and tail formation to stunted head, eye, and tail formation, distended pericardium, and unfolded heart tube. These studies demonstrate multiple critical roles for ErbB4 in development, and the utility of the zebrafish model system for these studies. AHA30137N, EY017732 , Case Aces/NSF Advance, Wadsworth Foundation.
Mild to moderate COVID-19 illness in adult outpatients
Blair, Janis E. , Gotimukul, Ashwini, Mina, Syeda A. , Bartels, Helen Caroline , Burns, Mark W. , Kole, Amy E., Vikram, Holenarasipur R. , Gea‐Banacloche, Juan , Seville, Maria Teresa , Petty, Skye A. Buckner, Vikram, Avinash, Orenstein, Robert , Wang, Fangfang, Bartels, Helen C, Vikram, Holenarasipur R. , Wang, Fangfang, Burns, Mark W., Kole, Amy

Mayo Clinic

Medicine | June 17, 2021 | Volume: 100 | Issue: 24 | Pages: e26371

10.1097/md.0000000000026371 | PMID 34128896 Get It

Abstract Most patients with coronavirus disease 2019 (COVID-19) have mild to moderate illness not requiring hospitalization. However, no study has detailed the evolution of symptoms in the first month of illness. At our institution, we conducted remote (telephone and video) visits for all adult outpatients diagnosed with COVID-19 within 24 h of a positive nasopharyngeal polymerase chain test for SARS-CoV-2. We repeated regular video visits at 7, 14, and 28 days after the positive test, retrospectively reviewed the prospective data collected in the remote visits, and constructed a week by week profile of clinical illness, through week 4 of illness. We reviewed the courses of 458 symptomatic patients diagnosed between March 12, 2020, and June 22, 2020, and characterized their weekly courses. Common initial symptoms included fever, headache, cough, and chest pain, which frequently persisted through week 3 or longer. Upper respiratory or gastrointestinal symptoms were much shorter lived, present primarily in week 1. Anosmia/ageusia peaked in weeks 2 to 3. Emergency department visits were frequent, with 128 visits in the 423 patients who were not hospitalized and 48 visits among the 35 outpatients (7.6%) who were eventually hospitalized (2 subsequently died). By the fourth week, 28.9% said their illness had completely resolved. After the 4-week follow up, 20 (4.7%) of the 423 nonhospitalized patients had further medical evaluation and management for subacute or chronic COVID-19 symptoms. Mild to moderate outpatient COVID-19 is a prolonged illness, with evolving symptoms commonly lasting into the fourth week of illness.
Insights into cAMP signaling in polycystic kidney disease from depletion and interaction studies of Phosphodiesterase 1A and Polycystin 2 in zebrafish
Leightner, Amanda C., Sussman, Caroline R. , Ward, Christopher J. , Harris, Peter C. , Torres, Vicente E.

Mayo Clinic

The FASEB Journal | June 16, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.910.6 Get It

Substantial evidence indicates the importance of elevated cAMP in polycystic kidney disease (PKD). Preclinical and clinical trials have shown the feasibility of therapies (vasopressin V2 receptor antagonists and somatostatin analogs) acting on G protein coupled receptors to inhibit adenylyl cyclase activity and production of cAMP. An additional or alternative approach could be to increase phosphodiesterase (PDE) mediated hydrolysis of cAMP. Of the large PDE superfamily, PDE1 is the only family activated by calcium, which is reduced in PKD cells. To assess the contribution of PDE1A to renal cyst formation, we depleted PDE1A levels using antisense morpholinos in zebrafish. We identified two splice isoforms with alternative starts corresponding to human PDE1A1 and PDE1A5. Two splice‐blocking morpholinos targeting the common hydrolase domain of both isoforms induced renal cysts. Two additional morpholinos, targeting each start, also induced renal cysts with dose dependence and additive effects. Co‐injection of the start 1 morpholino with pkd2 morpholino increased the severity of hydrocephalus, renal cysts, and body curvature, demonstrating functional interaction of PDE1A and PC2. Overall, data implicate PDE1A in PKD pathogenesis and validate further investigation of PDE1A as a therapeutic target in PKD.
Cerebral blood flow regulation during blood loss compared to lower body negative pressure in humans (1068.9)
Barnes, Jill N. , Johnson, Blair D. , Convertino, Víctor A. , Joyner, Michael J. , Rickards, Caroline A.

Mayo Clinic

The FASEB Journal | June 16, 2021 | Volume: 28 | Issue: S1 | Pages: No page available

10.1096/fasebj.28.1_supplement.1068.9 Get It

Lower body negative pressure (LBNP) is often used to simulate blood loss in humans. However, it is unknown if the effects of actual blood loss (BL) on cerebral blood flow regulation is analogous to simulated blood loss during LBNP. Nine healthy men (32±6 y) were studied at baseline, during 3 levels of LBNP (5 min each at ‐15, ‐30, ‐45 mmHg), and during 3 levels of blood loss (5 min each at 333, 667, 1000 mL). LBNP and BL conditions were randomized. Intra‐arterial mean arterial pressure (MAP) was similar during LBNP compared with BL (p>0.20). Central venous pressure (CVP; 2.8±0.7 vs. 4.0±0.8, 1.2±0.6 vs. 3.5±0.8, 0.2±0.9 vs. 2.1±0.9 mmHg for level 1, 2, and 3; p<0.01) and stroke volume (71±4 vs. 80±3, 60±3 vs. 74±3, 51±2 vs. 68±4 mL for level 1, 2, and 3; p<0.01) were lower during LBNP compared with BL. Despite differences in CVP, middle cerebral artery velocity (MCAv) and cerebrovascular conductance index (CVCi) were similar between LBNP and BL at each level (MCAv at level 3: 62±6 vs. 66±5 cm/s; p=0.37; CVCi at level 3: 0.72±0.05 vs. 0.73±0.05 cm/s/mmHg; p=0.29). Furthermore, the slope of the relationship between MAP and MCAv was not different between LBNP and BL (1.06 vs. 1.07 cm/s/mmHg). Our results suggest that the cerebral hemodynamic responses to LBNP are similar to actual blood loss. Grant Funding Source : Supported by U.S. Army MRMC Combat Casualty Care Research Program Grant # W81XWH‐11‐1‐0823
Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19
Prudencio, Mercedes , Marquez, Christopher P. , Jansen‐West, Karen , Franco-Mesa, Camila , White, Launia J. , Dunmore, Judith A. , Cook, Casey , Lilley, Meredith T. , Song, Yuping , Harlow, Caroline , Oskarsson, Björn , Nicholson, Katharine, Hoyne, Jonathan , Petrucelli, Leonard , Marquez, Christopher P , Jansen-West, Karen R , Franco-Mesa, Camila , White, Launia J , Dunmore, Judith A , Cook, Casey N , Harlow, Caroline F , Oskarsson, Björn , Wszolek, Z.K. , Hickson, LaTonya J , O'Horo, John C , Hoyne, Jonathan B , Gendron, Tania F , Meschia, James F , Petrucelli, Leonard , Prudencio, Mercedes , Lilley, Meredith T , Erben, Young , Heckman, Michael G. , Wszołek, Zbigniew K. , Hickson, LaTonya J. , O’Horo, John C. , Gendron, Tania F. , Meschia, James F.

Mayo Clinic

Science Translational Medicine | June 15, 2021 | Volume: 13 | Issue: 602 | Pages: No page available

10.1126/scitranslmed.abi7643 | PMID 34131052 Get It

Hospitalized patients with COVID-19 show increased serum concentrations of neurofilament light chain that correlate with worse clinical outcomes.
Correlation of Chronic Histologic Changes on Preimplantation Frozen Section Biopsy With Transplant Outcomes After Deceased Donor Kidney Transplantation
Ninan, Jacob, Smith, Maxwell L., Mathur, Amit K., Harbell, Jack W., Jadlowiec, Caroline C., Nair, Sumi Sukumaran, Moss, Adyr, Reddy, Kunam S., Heilman, Raymond L., Ninan, Jacob, Smith, Maxwell L., Mathur, Amit K., Harbell, Jack W., Jadlowiec, Caroline C., Nair, Sumi Sukumaran, Moss, Adyr, Reddy, Kunam S., Heilman, Raymond L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 4, 2021 | Volume: 146 | Issue: 2 | Pages: 205-212

10.5858/arpa.2020-0675-oa | PMID 34086859 Get It

Context.— It is unclear if preimplantation frozen section biopsy correlates with outcomes after deceased donor kidney transplantation. Objective.— To assess if chronic histologic changes on the preimplant frozen section correlates with graft loss and estimated glomerular filtration rate independently of kidney donor profile index (KDPI). Design.— Seven hundred three preimplantation biopsies were reviewed and a Banff sum score was calculated using glomerular sclerosis, interstitial fibrosis, vascular intimal thickening, and arteriolar hyalinosis. The posttransplant outcomes were compared for preimplantation biopsy Banff sum 0-1, 2-3, and 4-9. The cohort was also stratified by KDPI 85 or less versus more than 85. Results.— For the entire biopsy cohort, graft survival, estimated glomerular filtration rate at 1 year, and chronic changes on a 1-year posttransplant biopsy were superior in the group with preimplantation Banff sum 0-1. After stratifying by KDPI, the Banff sum no longer correlated with graft survival. In a univariate mode, using the Banff sum score as a continuous variable, a higher Banff sum score was significantly associated with graft failure (P = .03); however, after adjusting the KDPI, the Banff sum score no longer correlated with graft failure (P = .45). The 1-year estimated glomerular filtration rate and 1-year biopsy changes were superior in the group with Banff sum 0-1 only in the cohort with KDPI 85 or less. Conclusions.— In donor kidneys used for transplant, preimplantation biopsy chronic changes correlate with estimated glomerular filtration rate and biopsy findings at 1 year, but biopsies with mostly mild chronicity and Banff sum scores less than or equal to 5 did not impact graft survival beyond KDPI.
BRAFV600E frequency and impact on outcomes in adults with langerhans cell histiocytosis.
Abeykoon, Jithma P. , Davidge‐Pitts, Caroline , Schram, Susan, Acosta‐Medina, Aldo A. , Bennani, N. Nora , Koster, Matthew J. , Ravindran, Aishwarya , Rech, Karen L. , Ryu, Jay H. , Shah, Meera , Tobin, W. Oliver , Vassallo, Robert , Young, Jason R. , Go, Ronald S. , Goyal, Gaurav

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 7050-7050

10.1200/jco.2021.39.15_suppl.7050 Get It

7050 Background: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm manifesting as unifocal, multifocal, multisystem (MS) or pulmonary LCH (smoking-related). In pediatric LCH, somatic BRAFV600E prevalence is reported at 55-70%, and associated with increased risk of multisystem disease and early treatment failure. Our aim was to describe the prevalence of BRAFV600E mutation and evaluate its association with clinical manifestations and outcomes in adults with LCH. Methods: A retrospective review of adult patients diagnosed with LCH consecutively seen at Mayo Clinic from 2011 to 2020 was performed.Evaluation of association of BRAFV600E mutational status and clinical factors was conducted by the Chi-square test for independence. Progression-free survival (PFS) and overall survival (OS) were analyzed via the Kaplan Meier method and compared with the log-rank test to assess the effect of BRAFV600E. Results: Of the total LCH cohort ( n= 128), 88 patients with available BRAFV600E results were included in the study. Median age at diagnosis was 41y (range 19 - 88); 52.3% were male. 40 (45.5%) patients had a BRAFV600E mutation. Increasing age was associated with BRAFV600E (10-year increase OR 1.42, 95%CI 1.07-1.89; p= 0.017). No correlation was observed between BRAFV600E status and site of disease, risk organ (RO: liver, spleen, marrow) involvement, or MS disease. Patients with BRAFV600E were 4 times more likely to receive targeted therapy ( BRAF inhibitor) than non- BRAFV600E patients ( p= 0.018). After a median follow up of 46 mo (95% CI 30.8-61.2), PFS was similar between BRAFV600E and non- BRAFV600E patients ( p= 0.167). However, patients with BRAFV600E had a worse 3-year OS compared with non- BRAFV600E patients (84% vs. 97.1%, p= 0.027). Patients who died had a significantly higher age at LCH diagnosis (median 62 vs. 38 years; p= 0.0002). Conclusions: In our cohort of adults with LCH, BRAFV600E was less frequent than reported in pediatric literature and was associated with worse OS. The frequency of BRAFV600E was positively correlated with increasing age. Contrary to reports in pediatric LCH, there were no significant associations between BRAFV600E and high-risk or multisystem disease.[Table: see text]
PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).
Cubillo, Antonio , Petorin-Lesens, Caroline, Rodrı́guez-Salas, Nuria, Dupuis, Olivier , López, Carlos , Tournigand, Christophe , Isambert, Nicolás , Abubaker, Khalid, Schumacher, Karl-Maria, Berghoff, Karin , Vlassak, Soetkin, Otto, Gordon, Bekaii‐Saab, Tanios , Cutsem, Eric Van , Raghav, Kanwal , Dupuis, Olivier, Tabernero, Josep

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: TPS3616-TPS3616

10.1200/jco.2021.39.15_suppl.tps3616 Get It

TPS3616 Background: METamp is a secondary, or co-driving, genetic change in pts with mCRC and acquired resistance to anti-EGFR therapy, which can contribute to disease progression. In EGFR-resistant pts with mCRC and METamp, MET inhibition + an anti-EGFR agent may achieve disease control by targeting emerging MET pathway activation and maintaining EGFR pathway inhibition. Tepotinib is an oral, once-daily, highly selective, potent MET tyrosine kinase inhibitor (TKI), recently approved in the US for NSCLC harboring MET exon 14 skipping. Tepotinib + gefitinib demonstrated improved outcomes in pts with EGFR-mutant METamp NSCLC and acquired EGFR TKI resistance vs chemotherapy (INSIGHT: NCT01982955). In these pts, progression-free survival (PFS) was 16.6 vs 4.2 months (HR = 0.13; 90% CI: 0.04, 0.43) and overall survival (OS) was 37.3 vs 13.1 months (HR = 0.08; 90% CI: 0.01, 0.51). In pts with mCRC and acquired resistance to anti-EGFR antibody therapy due to METamp, tepotinib + anti-EGFR antibody cetuximab may be active and provide an effective therapeutic option. Methods: This Phase II, multicenter, single-arm, open-label study will assess preliminary safety and tolerability, antitumor activity, and explore pharmacokinetic (PK) profiles of tepotinib + cetuximab in pts with RAS/BRAF wild-type left-sided mCRC and acquired resistance to anti-EGFR antibody-targeted therapy due to METamp (NCT04515394). A safety run-in (6–12 pts) will evaluate the recommended Phase II dose of tepotinib to be used in combination with cetuximab (endpoint: dose-limiting toxicities). Enrollment is based on a confirmed advanced left-sided CRC diagnosis ( RAS/BRAF wild-type), documented previous anti-EGFR therapy and acquired resistance on most recent anti-EGFR antibody and METamp confirmed by liquid and/or tissue biopsy. Pts must be ≥18 years old, have ECOG PS of 0/1 and normal organ function. The study will screen sufficient pts to account for setting-specific heterogenecity in reported METamp incidence. Approximately 42 pts are planned to receive study treatment: ̃22 in Cohort A (second-line, outside US) and 20 in Cohort B (≥third-line, US only). Primary endpoint: investigator-assessed objective response (RECIST 1.1). Secondary endpoints are investigator-assessed duration of response (DoR), PFS (RECIST 1.1) and OS, tolerability and safety (NCI-CTCAE v5.0), and cetuximab immunogenicity (measured by antidrug antibody assays at the start and end of treatment). Additional endpoints include assessment of tepotinib and cetuximab PK profiles, and expression of biomarkers of resistance (from blood and/or tissue samples). Retrospective assessment of best overall response, DoR and PFS by an independent review committee may be conducted. No formal statistical hypothesis will be tested in this exploratory study. Clinical trial information: NCT04515394.